Partial
Partially Aligned
Patient Risk:
Low
Summary
Some claims are supported by the supplied label excerpts (ADHD indication, mixed amphetamine salts, multi-bead delayed/immediate release concept, once-daily administration is not shown in provided text, and cardiovascular monitoring is supported). Several claims about duration/day-long coverage and specific adverse effects as 'commonly include' are not supported by the provided label content.
Category Scores
Accurate Statements
Mydayis is the brand name for a long-acting form of mixed amphetamine salts.
Supported partially: label describes MYDAYIS as extended-release capsules containing mixed salts of a single-entity amphetamine (11 DESCRIPTION). Long-acting aspect is not explicitly stated in the provided excerpt.
Mydayis is used to treat ADHD (attention-deficit/hyperactivity disorder).
MYDAYIS is indicated for treatment of ADHD (1 INDICATIONS AND USAGE).
Mydayis uses a multi-phase release dosing system.
Label states capsules contain three types of drug-releasing beads: an immediate release and two different types of delayed release (11 DESCRIPTION).
Mydayis can cause stimulant-related side effects.
Supported generally by the label excerpt that CNS stimulants increase blood pressure and heart rate and that monitoring is required (5.3 Increased Blood Pressure and Heart Rate).
Clinicians typically monitor blood pressure with Mydayis.
Monitor all MYDAYIS-treated patients for potential tachycardia and hypertension (5.3).
Clinicians typically monitor heart rate with Mydayis.
Monitor all MYDAYIS-treated patients for potential tachycardia and hypertension; and CNS stimulants increase heart rate (5.3).
Unsupported Statements
Mydayis is designed to last longer than many standard once-daily stimulant formulations.
Not supported by the provided label excerpts.
Mydayis is intended to provide symptom control through more of the day on a single schedule.
Not supported by the provided label excerpts.
Mydayis is built as a longer-duration formulation intended for day-long coverage.
Not supported by the provided label excerpts.
Mydayis is intended to provide symptom control from morning through afternoon/evening.
Not supported by the provided label excerpts.
Mydayis is a once-daily option.
Once-daily dosing is not stated in the provided excerpts (only safety exposure includes per-day dosing ranges in 6.1, not frequency).
Stimulant-related side effects of Mydayis commonly include appetite loss.
No adverse reaction frequency/list including appetite loss is present in the provided label excerpts.
Stimulant-related side effects of Mydayis commonly include insomnia.
No adverse reaction frequency/list including insomnia is present in the provided label excerpts.
Stimulant-related side effects of Mydayis commonly include increased heart rate.
Increased heart rate is supported as a physiologic effect (5.3) but not characterized as a 'commonly include' adverse reaction in the provided excerpts.
Stimulant-related side effects of Mydayis commonly include anxiety/jitteriness.
No adverse reaction frequency/list including anxiety/jitteriness is present in the provided label excerpts.
Stimulant-related side effects of Mydayis commonly include stomach upset.
No adverse reaction frequency/list including stomach upset is present in the provided label excerpts.
Clinicians typically monitor weight/appetite with Mydayis.
No monitoring recommendation for weight/appetite is present in the provided excerpts.
Clinicians typically monitor sleep with Mydayis.
No monitoring recommendation for sleep is present in the provided excerpts.
Clinicians typically monitor overall symptom response with Mydayis.
No monitoring recommendation for symptom response is present in the provided excerpts.
Contradictions
Important Omissions
Dose frequency (e.g., once daily) and specific dosing regimen are not provided in the supplied excerpts, yet multiple statements rely on assumed daily scheduling/duration.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only safety-related label support in the provided excerpts is cardiovascular effects and monitoring (blood pressure/heart rate). Claims about specific 'commonly include' adverse effects and other monitoring items are unsupported by the supplied text; this creates potential misinformation but does not directly contradict the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Duration/day-long coverage and once-daily scheduling are asserted without support in the provided label excerpts; several 'commonly include' adverse effects and monitoring recommendations are not supported by the supplied text.
Suggested Improvement
Restrict descriptions to what is explicitly supported (extended-release capsule with immediate + two delayed release bead types; ADHD indication for patients 13 years and older; monitor for hypertension/tachycardia). Avoid asserting day-long coverage, once-daily dosing, or specific adverse effects as 'commonly' and avoid specifying additional monitoring (weight/appetite, sleep, symptom response) unless present in the provided label.